Evidence map›Paper›PMID 38785315›Full record

ArticleHistology and histopathology2025

Association of low angiomotin-p130 and high YAP1 nuclear expression with adverse prognosis in epithelial ovarian cancer.

Junna Cai, Xiaorui Han, Meng Li, Xiaoli Liu, Fengying Zhang, Xiaohua Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Junna CaiDepartment of Obstetrics and Gynecology, Hebei Medical University, Shijiazhuang, PR China.
Xiaorui HanDepartment of Obstetrics and Gynecology, Xingtai People's Hospital, Xingtai, Hebei, PR China.
Meng LiDepartment of Obstetrics and Gynecology, Xingtai People's Hospital, Xingtai, Hebei, PR China.
Xiaoli LiuDepartment of Obstetrics and Gynecology, Xingtai People's Hospital, Xingtai, Hebei, PR China.
Fengying ZhangDepartment of Obstetrics and Gynecology, Xingtai People's Hospital, Xingtai, Hebei, PR China.
Xiaohua WuDepartment of Obstetrics and Gynecology, Hebei Medical University, Shijiazhuang, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of our study was to examine the association of Angiomotin (Amot-p130) and Yes-associated protein 1 (YAP1) expressions and their prognostic significance in epithelial ovarian cancer (EOC).

methodsA total of 100 primary EOC samples were obtained for immunohistochemical analysis of Amot-p130 and YAP1 expressions. Correlation analysis was performed between Amot-p130 or YAP1 and clinical factors. The overall survival time was calculated.

resultsLow Amot-p130 and high YAP1 nuclear expression were identified in 34 and 56 of 100 EOC tissues, respectively. Both low Amot-p130 and high YAP1 nuclear expression were associated with advanced tumor stage, high-grade carcinoma, and non-response to chemotherapy (

conclusionsLow Amot-p130 and high YAP1 nuclear expression can provide additional prognostic information for patients with EOC. A marker of low Amot-p130 and high YAP1 expression may be a potent predictor of poor prognosis in patients with epithelial ovarian cancer.

Indexed as

Adaptor Proteins, Signal TransducingAngiomotinsBiomarkers, TumorCarcinoma, Ovarian EpithelialOvarian NeoplasmsPhosphoproteinsTranscription FactorsYAP-Signaling ProteinsAdultAgedCell NucleusFemaleHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedAdaptor Proteins, Signal TransducingAMOT protein, humanAngiomotinsBiomarkers, TumorPhosphoproteinsTranscription FactorsYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID38785315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.